Clinical Trial Update: A Study of IMR-687 in Subjects With Beta Thalassemia [Phase 2]

View source ↗

Summary

Phase 2 study of IMR-687 in Beta-thalassemia was terminated; results have been posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• IMR-687

Snippet

Sponsor: Cardurion Pharmaceuticals, Inc. | Conditions: β Thalassemia | Phase 2 | Status: TERMINATED | Results posted: 2022-06-30